<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318041</url>
  </required_header>
  <id_info>
    <org_study_id>DAR-THA-19-01</org_study_id>
    <nct_id>NCT04318041</nct_id>
  </id_info>
  <brief_title>Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients</brief_title>
  <official_title>Evaluation of the Structural Modification Effect of Diacerein (Artrodar®) in Knee Osteoarthritic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TRB Chemedica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TRB Chemedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the structure-modifying effect of Diacerein (Artrodar ®) in knee
      osteoarthritic (OA) patients by measuring total cartilage volume from magnetic resonance
      imaging (MRI) of the knee. Half of participants will receive Diacerein (Artrodar ®), while
      the other half will receive a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diacerein (Artrodar ®) participants take 1x1 with evening meal for 1 month (D1-D28) then 1x2
      with morning and evening meal for 23 months (D29-end of study). Placebo participants take 1x1
      with evening meal for 1 month (D1-D28) then 1x2 with morning and evening meal for 23 months
      (D29-end of study).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigator, hospital pharmacists and monitors are blind to the treatment. The analysis of the results will be performed blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cartilage volume measured by MRI of the affected knee.</measure>
    <time_frame>Change from Day 0 cartilage volume at Day 336, Day 672</time_frame>
    <description>Cartilage volume in cc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marrow lesions measured by MRI of the affected knee.</measure>
    <time_frame>Change from Day 0 Bone marrow lesions at Day 336, Day 672</time_frame>
    <description>Bone marrow lesions in mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Synovitis measured by MRI of the affected knee.</measure>
    <time_frame>Change from Day 0 Synovial tissue volume at Day 336, Day 672</time_frame>
    <description>Synovial tissue volume in mm3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Joint space width at narrowest point at medial compartment measured by X-ray (Full extension, weight-bearing position)</measure>
    <time_frame>Change from Day -7 to -30 Joint space width at Day 168, Day 336, Day 504, Day 672</time_frame>
    <description>Joint space width in mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain at rest</measure>
    <time_frame>Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
    <description>Visual analogue scale (VAS) 0-100 mm. 0 is no pain, 100 is extreme pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain on walking at 15 meters</measure>
    <time_frame>Day -7 to -30, Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
    <description>Visual analogue scale (VAS) 0-100 mm. 0 is no pain, 100 is extreme pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOs</measure>
    <time_frame>Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
    <description>Knee and Osteoarthritis Outcome Score from 1-5 Likert scale score with higher scores denoting worse pain and disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ5D5L</measure>
    <time_frame>Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
    <description>EQ5D5L is a standardized instrument for measuring generic health status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time up-and-go test</measure>
    <time_frame>Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician and Patient's global assessment</measure>
    <time_frame>Day 168, Day 336, Day 672</time_frame>
    <description>Visual analogue scale (VAS) 0-100 mm to assess efficacy and tolerability by physician and patient. 0 is not effective/ no tolerate, 100 is very effective/ very good.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescued medicine consumption</measure>
    <time_frame>Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Knee Questionnaire</measure>
    <time_frame>Day 0, Day 28, Day 84, Day 168, Day 252, Day 336, Day 420, Day 504, Day 588, Day 672</time_frame>
    <description>1-5 Likert scale score with higher scores denoting worse pain and disability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>diacerein (Artrodar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artrodar</intervention_name>
    <description>Diacerein (Artrodar):
D1-D28 (1 month): Artrodar (50 mg) 1 x 1 with evening meal D29-end of study (23 months): Artrodar (50 mg) 1 x 2 with meal</description>
    <arm_group_label>diacerein (Artrodar)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo:
D1-D28 (1 month): Placebo 1 x 1 with evening meal D29-end of study (23 months) Placebo 1 x 2 with meal</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged between 40 and 65 years who diagnosed with primary OA knee (medial
             tibiofemoral compartment) according to ACR criteria

          2. Grade II-III OA severity that classified by the Kellgren-Lawrence classification

          3. Varus malalignment ≤ 15°

          4. Body mass index (BMI) ≤ 30 kg/m2

          5. Pain on walking at 15 metres ≥ 30 mm using 100 mm visual analogue pain score (VAPS)

          6. Evidence of adequate contraceptive methods in women of childbearing age

        Exclusion Criteria:

          1. Accompanying osteoarthritis of the hip of sufficient severity to interfere with the
             functional assessment of the knee

          2. Intra-articular treatment with any product (corticosteroids in the last 3 months,
             glycosaminoglycans, hyaluronic acid in the last 6 months, etc.), joint lavage or
             arthroscopic procedures within 6 months before the start of the study

          3. Oral corticosteroids, oral symptomatic slow acting drug for OA (SYSADOA) treatment
             (chondroitin sulfate, glucosamine sulfate, piascledin, diacerein) within last 3 months

          4. Current treatment with anti-depressants, tranquilisers, antacids or antibiotics

          5. Poor general health or other conditions which would make regular hospital attendance
             difficult

          6. Primary inflammatory painful conditions of the knee (e.g. rheumatoid arthritis,
             psoriatic arthropathy, pseudo-gout)

          7. Painful knee conditions other than osteoarthritis (e.g. Sudeck's atrophy,
             intra-articular neoplasm, villonodular synovitis)

          8. Evolving arthritis requiring surgery within the coming year;

          9. Persistent diarrhoea (&gt; 3 stools /24 h) or laxative use (any laxative use is to be
             stopped before inclusion in the trial)

         10. Severe gastrointestinal disorders, indications or history of severe gastrointestinal
             disorders (e.g. gastric or duodenal ulcers, ulcerative colitis, Crohn's syndrome,
             diverticulitis, recurrent pancreatitis)

         11. Renal insufficiency (estimate glomerular filtration rate ≤ 60 ml/min/1.73 m2)

         12. Hepatic disease (transaminases &gt; 2.5 x upper limit of normal values (ULN) or total
             bilirubin &gt; 2 x ULN) or history of alcoholism and liver disease

         13. Severe parenchymal organ disease

         14. History of heart attack or stroke, or have had serious diseases of the heart such as
             congestive heart failure, or taking clopidogrel.

         15. Patient with diabetes mellitus (DM) who has heamoglobin A1c level &gt; 8%

         16. Patient with hypertension who has systolic blood pressure &gt; 150 mmHg or diastolic
             Blood pressure &gt; 95 mmHg

         17. Pregnancy or lactation

         18. Participation in a drug clinical trial within the 3 months before the start of the
             study;

         19. Ascertained hypersensitivity to the active ingredient diacerein, to similar compounds,
             to the excipients or to paracetamol, naproxen, and omeprazole

         20. Contraindications for magnetic resonance imaging (MRI) assessment such as heart
             pacemaker, aneurysm clip or claustrophobia

         21. Knee size measured at lower thigh &gt; 50 cm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nipaporn Jitsook</last_name>
    <role>Study Director</role>
    <affiliation>TRB Chemedica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juree Patarasuwankul</last_name>
    <phone>+66 (0)2 264 20 10</phone>
    <email>juree.p@trbchemedica.co.th</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

